# Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee

> **NCT04120402** · PHASE2 · COMPLETED · sponsor: **Eupraxia Pharmaceuticals Inc.** · enrollment: 318 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** EP-104IAR 25 mg
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT04120402
- **Lead sponsor:** Eupraxia Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2023-05-17
- **Final completion:** 2023-06-01
- **Target enrollment:** 318 (ACTUAL)
- **Last updated:** 2024-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120402, "Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04120402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*